MaaT Pharma SA (MAAT.PA)
EUR 8.1
(1.0%)
EUR 8.1
(1.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -19.74 Million EUR | -81.23% |
| 2022 | -13.31 Million EUR | -52.85% |
| 2021 | -8.71 Million EUR | -68.44% |
| 2020 | -6.58 Million EUR | -2.91% |
| 2019 | -6.76 Million EUR | -14.31% |
| 2018 | -5.09 Million EUR | 7.12% |
| 2017 | -4.65 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -6.31 Million EUR | -11.81% |
| 2024 Q2 | -6.31 Million EUR | 0.0% |
| 2023 Q1 | -4.21 Million EUR | 49.02% |
| 2023 Q2 | -11.07 Million EUR | -162.54% |
| 2023 FY | - EUR | -81.23% |
| 2023 Q3 | -5.65 Million EUR | 48.96% |
| 2023 Q4 | -5.65 Million EUR | 0.0% |
| 2022 FY | - EUR | -52.85% |
| 2022 Q4 | -8.27 Million EUR | -174.02% |
| 2022 Q3 | -3.01 Million EUR | 66.36% |
| 2022 Q2 | -8.97 Million EUR | -146.7% |
| 2022 Q1 | -3.63 Million EUR | 38.64% |
| 2021 Q4 | -5.92 Million EUR | -146.48% |
| 2021 FY | - EUR | -68.44% |
| 2021 Q3 | -2.4 Million EUR | 52.14% |
| 2021 Q2 | -5.02 Million EUR | -157.68% |
| 2021 Q1 | -1.95 Million EUR | 51.36% |
| 2020 FY | - EUR | -2.91% |
| 2020 Q3 | -1.53 Million EUR | 52.36% |
| 2020 Q2 | -3.21 Million EUR | -208.15% |
| 2020 Q1 | -1.04 Million EUR | 0.0% |
| 2020 Q4 | -4.01 Million EUR | -161.92% |
| 2019 FY | - EUR | -14.31% |
| 2018 FY | - EUR | 7.12% |
| 2017 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.29 Million EUR | -500.0% |
| ABIVAX Société Anonyme | -133.2 Million EUR | 85.181% |
| Adocia SA | -22.73 Million EUR | 13.162% |
| Aelis Farma SA | -6.34 Million EUR | -211.013% |
| Biophytis S.A. | -13.8 Million EUR | -43.002% |
| Advicenne S.A. | -6.24 Million EUR | -216.143% |
| genOway Société anonyme | 6.35 Million EUR | 410.829% |
| IntegraGen SA | -52.5 Thousand EUR | -37497.852% |
| Medesis Pharma S.A. | -3.84 Million EUR | -413.41% |
| Neovacs S.A. | -8.44 Million EUR | -133.622% |
| NFL Biosciences SA | -4.04 Million EUR | -387.491% |
| Plant Advanced Technologies SA | 72.53 Thousand EUR | 27316.324% |
| Quantum Genomics Société Anonyme | -2.87 Million EUR | -586.972% |
| Sensorion SA | -22.31 Million EUR | 11.535% |
| Theranexus Société Anonyme | -7.38 Million EUR | -167.218% |
| TME Pharma N.V. | -5.07 Million EUR | -289.196% |
| Valbiotis SA | -6.95 Million EUR | -183.825% |
| TheraVet SA | -517.33 Thousand EUR | -3715.702% |
| Valerio Therapeutics Société anonyme | -18.91 Million EUR | -4.356% |
| argenx SE | -199.5 Million EUR | 90.106% |
| BioSenic S.A. | -6.79 Million EUR | -190.465% |
| Celyad Oncology SA | -7.76 Million EUR | -154.283% |
| DBV Technologies S.A. | -79.53 Million EUR | 75.179% |
| Galapagos NV | 51.03 Million EUR | 138.678% |
| Genfit S.A. | -28.05 Million EUR | 29.628% |
| GeNeuro SA | -14.31 Million EUR | -37.871% |
| Hyloris Pharmaceuticals SA | -14.98 Million EUR | -31.776% |
| Innate Pharma S.A. | -7.57 Million EUR | -160.491% |
| Inventiva S.A. | -101.84 Million EUR | 80.618% |
| MedinCell S.A. | -20.04 Million EUR | 1.526% |
| Nanobiotix S.A. | -34.01 Million EUR | 41.974% |
| Onward Medical N.V. | -35.23 Million EUR | 43.975% |
| Oryzon Genomics S.A. | -4.43 Million EUR | -345.261% |
| OSE Immunotherapeutics SA | -23.26 Million EUR | 15.155% |
| Oxurion NV | -16.72 Million EUR | -17.999% |
| Pharming Group N.V. | 4.98 Million EUR | 496.309% |
| Poxel S.A. | -12.17 Million EUR | -62.082% |
| GenSight Biologics S.A. | -21.73 Million EUR | 9.158% |
| Transgene SA | -27.02 Million EUR | 26.954% |
| Financière de Tubize SA | 184.57 Thousand EUR | 10795.071% |
| UCB SA | 1.26 Billion EUR | 101.556% |
| Valneva SE | -64.51 Million EUR | 69.403% |
| Vivoryon Therapeutics N.V. | -28.35 Million EUR | 30.378% |